Mitsubishi Tanabe Transfers Three Drugs To Generic Subsidiary
This article was originally published in PharmAsia News
Executive Summary
To boost efficiency and better compete with generic alternatives, Mitsubishi Tanabe transferred three established drugs whose patents have expired to its generic subsidiary